NovoEight Shortage: What Providers and Prescribers Need to Know in 2026

For hematologists, HTC physicians, and other prescribers managing patients with hemophilia A, navigating the factor VIII treatment landscape in 2026 requires staying current on product availability, insurance formulary dynamics, and access programs. This clinical overview focuses on NovoEight (turoctocog alfa) and what your patients may experience when trying to access this therapy.

Current NovoEight Availability Status

NovoEight is not currently listed on the FDA's drug shortage database. Manufactured by Novo Nordisk and distributed exclusively through specialty pharmacies, NovoEight benefits from a controlled distribution model that typically insulates it from the supply chain disruptions that affect commodity generics and sterile injectables.

However, access barriers are real and may present clinically as delayed prescriptions, coverage lapses, or patients presenting undertreated. These access-related issues are distinct from a supply shortage but functionally disruptive for patients and their management plans.

Distribution Model and Specialty Pharmacy Landscape

NovoEight is dispensed exclusively through specialty pharmacies, including CVS Specialty, Accredo, BioMatrix, Option Care Health, and HTC-affiliated pharmacy programs. Insurance carriers typically designate specific specialty pharmacies for hemophilia products, and patients must use in-network pharmacies to maintain coverage.

NovoEight is available in six vial strengths: 250, 500, 1,000, 1,500, 2,000, and 3,000 IU. Stocking of all six strengths varies by pharmacy. When writing prescriptions, specify vial strength clearly and consider verifying with the specialty pharmacy that the prescribed strength is in inventory.

Formulary Dynamics in 2026: Competitive Pressure on NovoEight

The hemophilia A treatment landscape has shifted significantly. The emergence of extended half-life (EHL) factor products (Altuviiio, Esperoct, Jivi, Eloctate) and non-factor therapies (Hemlibra, Hympavzi, Qfitlia) has created formulary complexity at the payer level. Some insurance plans have tiered NovoEight in response to these alternatives.

Providers should be aware that some PBMs and health plans are applying step therapy requirements or quantity limits for NovoEight. For patients new to therapy or switching coverage, expect prior authorization requirements and potential step therapy protocols requiring documentation of clinical need for this specific product.

Prior Authorization: Documentation Essentials

To support PA submissions for NovoEight, include documentation of:

Confirmed diagnosis of hemophilia A with factor VIII activity level

Current inhibitor status (Bethesda assay within the last 12 months)

Annualized bleeding rate (ABR) on current or proposed therapy

Clinical rationale for NovoEight specifically (e.g., portability/travel needs given 104°F storage stability, established efficacy, no inhibitor history)

Prior treatment history and response (for previously treated patients)

NovoCare (1-844-668-6732) offers dedicated reimbursement support and can assist your team with prior authorization submission and appeal documentation.

Distinguishing NovoEight From Its Successor: Esperoct

Novo Nordisk markets both NovoEight (standard half-life, every-other-day prophylaxis) and Esperoct (extended half-life, every-4-day prophylaxis). Both share the turoctocog alfa molecule — Esperoct adds glycoPEGylation to extend half-life. For patients tolerating NovoEight with adequate bleed control who desire fewer infusions, transitioning to Esperoct may be clinically appropriate and insurance-feasible given shared molecular lineage.

Patient Assistance Programs for Uninsured or Underinsured Patients

For patients without adequate coverage, Novo Nordisk's NovoCare program offers several access pathways:

NovoSecure PAP: Free medication for qualifying uninsured or underinsured patients. Applications via fax to 1-866-488-6576.

JumpStart Program: Short-term free supply for patients initiating therapy who are awaiting insurance approval.

Interim Program: Continued supply during gaps in commercial insurance coverage.

Copay Savings Card: Commercially insured patients can pay as little as $0 per fill, up to $12,000 in savings per calendar year.

How medfinder Supports Patient Access for Your Practice

When patients call your office unable to locate their factor fill, medfinder for providers can reduce that burden by calling pharmacies on patients' behalf and delivering results directly to them. This supports care continuity and reduces the time your staff spends on pharmacy coordination calls.

See our companion clinical guide: How to Help Your Patients Find NovoEight in Stock: A Provider's Guide.